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Abstract
Heated tobacco products (HTPs) are tobacco products that produce an emission containing nicotine and other 
chemicals, which is then inhaled by users. HTPs are a re-emerging class of tobacco products marketed as 
so-called potentially reduced-exposure products, or even as modified-risk tobacco products. Currently there 
is insufficient evidence to conclude that HTPs are less harmful than conventional cigarettes. In fact, there are 
concerns that while they may expose users to lower levels of some toxicants than conventional cigarettes, 
they also expose users to higher levels of other toxicants. It is not clear how this toxicological profile translates 
into short- and long-term health effects. The Conference of the Parties to the WHO Framework Convention on 
Tobacco Control (WHO FCTC) recognizes HTPs as tobacco products and therefore considers them to be subject 
to the provisions of the WHO FCTC.
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1Introduction
Processed tobacco in heated tobacco products (HTP)1 
is heated without reaching ignition to produce an 
emission containing nicotine and other chemicals, 
which is then inhaled by users. HTPs are a re-emerging 
class of tobacco products marketed as so-called 
potentially reduced-exposure products, or even as 
modified-risk tobacco products. 
This class of products is defined as re-emerging because 
at the time of this brief, HTPs were conceptually 
and technologically an evolution of similar products 
tobacco companies marketed through the 1980s and 
1990s. Back then, the precursors of these products 
were unsuccessful, and their sale discontinued. The 
emerging HTPs, however, are expected to capture a 
significant market share. 
Total sales for HTPs in 2016 were US$ 2.1 billion, 
and they are expected to reach US$ 17.9 billion by 
2021 (1). They stand a better chance of profitable 
marketing today because the tobacco industry is 
riding partly on the popularity of electronic nicotine 
and non-nicotine delivery systems (EN&NNDS) in 
some countries. Although an entirely different class 
of product, EN&NNDS have changed social norms and 
perceptions about conventional cigarette-smoking and 
the use of devices to deliver nicotine in many countries.
Only a few HTPs have been marketed so far (1). Japan 
Tobacco International (JTI) introduced the Ploom in 
2013 jointly with a firm known as Pax Labs, which has 
continued independently to market the PAX brand. 
JTI relaunched the Ploom independently in 2016. 
Philip Morris International (PMI) launched IQOS (I Quit 
Ordinary Smoking) in 2014. British American Tobacco 
(BAT) first marketed iFuse in Romania in 2015. Later, 
BAT marketed Glo in Asia. The Korea Tobacco and 
Ginseng Corporation (KT&G) is the latest incomer to 
the HTP market with the lil HTP in 2017 (2). Currently, 
HTPs are marketed in about 40 countries and IQOS 
is present in most of them.
¹ The tobacco industry calls HTPs “heat-not-burn” products.
There is not much information about the prevalence 
of HTP use and less about its trends. In Japan, 0.3% 
of the population aged 15–69 years reported using 
IQOS in the last 30 days (current use) in 2015 (3). 
Two years later, this figure was 3.6%. In 2017, 1.2% 
were currently using Ploom and 0.8% Glo (4). These 
figures are not mutually exclusive. In Italy, 1.4% of 
the population aged ≥ 15 years tried IQOS in 2017. 
Overall, 1.0% of never-smokers, 0.8% of ex-smokers 
and 3.1% of current cigarette smokers had tried IQOS 
(5).  In Germany, 0.3% of current smokers and recent 
ex-smokers aged 14 years or more currently used 
HTPs in 2017 (6). In Great Britain, 1.7% of adults had 
tried or were using HTPs in 2017, but only 13% of them 
had been using it daily (7). Three months after the 
introduction of IQOS in the Republic of Korea in 2017, 
3.5% of young adults aged 19–24 years were current 
users, although all of them also used conventional 
cigarettes and EN&NNDS (8).
Smoking, the traditional way of extracting nicotine 
by burning tobacco, results in smoke containing 
thousands of compounds, many of which are harmful 
to health. HTPs are based on the principle that burning 
tobacco is unnecessary to liberate nicotine. In smoking, 
aerosolizing nicotine is achieved by igniting tobacco, 
reaching temperatures of up to 900 oC in the burning 
cone, but a similar release is attained in HTPs by the 
volatilization and even pyrolysis (9) of tobacco at 
temperatures of around 350 oC, although in some 
products it may reach up to 550 ºC (10). The lower 
temperature at which nicotine is volatilized is expected 
to expose the user to emissions that have fewer 
toxicants and in smaller amounts than in conventional 
cigarette smoking. The essential difference between 
HTPs and EN&NNDS is that the former uses tobacco 
leaf while the latter does not.
This brief provides a summary of existing evidence 
of the ingredients, emissions and health effects of 
HTPs, with a review of policy options for regulation.
Introduction
2Separation between carbon and tobacco
MouthpieceTobacco-leaf 
filler
Carbon
tip
FIG. 1.  HTP type 1
There are four types of HTPs, depending on how tobacco is 
heated to deliver nicotine to the user’s lungs (11). The first 
is a cigarette-like device with an embedded heat source 
that can be used to aerosolize nicotine. The heat is provided 
by a pressed carbon-tip heat source located at the end 
of the product, which must be lighted like a conventional 
cigarette with a standard match or lighter (Fig. 1). Once 
lit, heat is transferred from the carbon tip to the tobacco, 
which is not in contact. The resulting temperature of about 
350 °C generates an emission infused with nicotine that 
is inhaled through the mouthpiece. No electrical system 
is used. After use, the product needs to be extinguished 
and discarded (12).
Types 
of HTPs
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3The second type uses an external heat source to aerosolize nicotine from 
specially designed cigarettes. This is the basic design of IQOS (13) (Fig. 2) and 
Glo (14). The tobacco used in PMI’s HTP is apparently not typical tobacco cut-
filler but rather a reinforced web of cast-leaf tobacco (a type of reconstituted 
tobacco) that includes 5–30% by weight of compounds that form emissions, 
such as polyols, glycol esters and fatty acids. In IQOS, the tobacco is heated 
by a blade in the heater device inserted into the end of the heat stick (or 
tobacco-containing element) so that the heat dissipates through the tobacco 
plug on a puff. The emission then passes through a hollow acetate tube and 
a polymer film filter on the way to the mouth. BAT describes its Glo product 
as a heating tube consisting of two separately controlled chambers that 
are activated by a button on the device to reach the operating temperature 
(240 °C) within 30–40 seconds. FIG. 2.  HTP type 2
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A third type uses a heated sealed chamber like a micro-oven (Fig. 3). A battery 
supplies the power to heat the chamber that transfers the heat through 
physical contact to any material the user places inside. The user must fill 
the micro-oven with the grounded tobacco leaf to aerosolize nicotine. The 
emission is then inhaled by the user through the mouthpiece. This is how dry-
herb or loose-leaf vaporizers, such as Pax, work (15). Unlike the other HTPs, 
the manufacturer does not provide or recommend any of the materials to fill 
the chamber of the liquid insert.
A fourth type uses a technology similar to EN&NNDS to derive flavour 
elements from small amounts of tobacco. BAT’s iFuse product (16) appears 
to be a hybrid ENDS–tobacco product in which the emission is passed over 
tobacco to heat it and pick up the flavour and is then inhaled by the user. The 
JTI Ploom TECH operates in a similar manner (17).FIG. 3.  HTP type 3
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emission 
content
Potentially toxic substances 
in mainstream emission
HTPs’ emission contains almost the same number of harmful and potentially 
harmful compounds (HPHCs) than conventional cigarette smoke, although in 
some cases at a lower level. A systematic review of published peer-reviewed 
papers shows that the levels of analysed toxicants were at least 62% lower 
than in cigarette smoke and particulate matter (PM) was 75% lower than in 
conventional cigarette smoke (18). Both tobacco-industry and independently 
funded studies, including some government institutions in Germany (19), the 
Netherlands (20) and the United Kingdom (21), found lower levels of toxicants 
in HTP emission than in cigarette smoke. The independent studies nevertheless 
reported less tar but more tobacco-specific nitrosamines and, apparently, 
acetaldehyde, acrolein and formaldehyde than industry-affiliated studies (18). 
Nicotine delivery
The mainstream emission from IQOS seems to deliver less nicotine per stick 
than a conventional cigarette. In studies, nicotine in mainstream emission 
ranged from 57–83% of that of a reference cigarette. Glo and iFuse deliver 
less nicotine than IQOS (19–23% of that of a conventional cigarette). HTPs 
deliver more nicotine than early generations of ENDS (18). No comparison is 
available for third-generation ENDS. Nicotine delivery measurements were 
similar in the tobacco industry and independently funded studies (18). 
Studies with humans that measured plasma nicotine levels after use of HTPs 
indicate that nicotine delivery of HTPs varies by brand but is always lower 
than that supplied by a conventional cigarette, except for IQOS. Nicotine 
delivered by HTPs attained peak concentration in plasma as quickly as with 
conventional cigarettes (18).
HTP emission content
6Potentially toxic substances in 
side-stream and second-hand emission
Like conventional cigarettes, but unlike EN&NNDS, analysed HTPs generate 
a side-stream emission. Three studies (one independently funded and two 
affiliated to the tobacco industry) reported the levels of some HPHCs in IQOS 
and Glo. All of them found that formaldehyde and acetaldehyde were present 
in the second-hand emission, although at a level about 10–20 times lower 
than in cigarette smoke, respectively. Only the independent study found PM 
and acrolein in the second-hand emission; in this study, PM was about four 
times lower than in cigarette smoke and acrolein about 50 times lower (18). 
Consequently, the evidence suggests that second-hand emission from HTPs 
expose bystanders to quantifiable levels of PM and key toxicants but at a 
lower level than from second-hand smoke of combustible tobacco products.
 The number of toxicants measured so far in peer-review articles does not 
cover the full range of HPHCs of interest. For example, PMI reported in its 
submission to the United States Food and Drug Administration (FDA) on 
40 of the 93 HPHCs in IQOS mainstream emission recommended by the 
agency. The levels of the missing 53 HPHCs, of which 50 are carcinogenic, 
are unknown (22).
 The reports submitted by PMI to the FDA include levels of 57 other 
constituents that are not included in the FDA’s list of HPHCs. The level of 
56 of them was higher in IQOS emissions than in conventional cigarettes. 
Their levels were double those in the reference conventional cigarettes for 
22 compounds and more than 10 times higher for seven. It appears that 
IQOS reduces exposure to some toxicants but elevates exposure to other 
substances. A number of these substances belong to chemical classes 
that are known to have significant toxicity, but in general, there is limited 
information on the toxicity of many of them (22). 
The finding of a lower 
level of toxicants in 
HTP emission must 
be qualified by the 
following caveats.
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use on health
Health risks from exposure 
to HTP second-hand emission
There is no available evidence to indicate whether HTP use is associated 
with any long-term clinical outcomes from exposure to the second-hand 
emission. HTPs nevertheless generate side-stream emission with ultrafine 
particles and a number of harmful toxicants, although at a lower level than 
in conventional cigarettes. A recent study found that a proportion of people 
exposed to second-hand IQOS emissions experienced short-term symptoms 
such as sore throat, eye pain and feeling ill (4). 
Given that a number of public health organizations, including WHO (27,28),  
have deemed that no level of side-stream exposure is safe or acceptable, 
these findings are clearly concerning and merit further study.
Nicotine delivery
The nicotine delivery profile of some (but not all) HTPs, particularly IQOS, 
approximates to that of conventional cigarettes. Some HTPs therefore might 
be adequate substitutes for cigarettes in the delivery of nicotine, although user 
satisfaction is reported to be lower than for conventional tobacco products.
Health risks to HTP users from 
exposure to mainstream emission
There is no available evidence to conclude whether HTP use is associated with any 
long-term clinical outcome, positive or negative, from exposure to the mainstream 
emission. One PMI study claimed that IQOS, compared to smoking a conventional 
cigarette, reduced biomarkers associated with endothelial dysfunction, oxidative 
stress, inflammation and high-density lipoprotein and cholesterol counts (23). 
PMI also claimed in the submission to the United States FDA that “human 
clinical studies have confirmed that clinical markers of … inflammation show 
positive changes, similar to those seen following smoking abstinence.” A critical 
review of PMI’s data concluded, however, that PMI presented no human clinical 
data directly from the lung. It also concluded that in human users, there was no 
evidence of improvement in pulmonary inflammation or pulmonary function in 
cigarette smokers who switched to IQOS. PMI’s claim that smokers who switch 
to IQOS reduce inflammation and the risk of chronic obstructive pulmonary 
disease therefore is not supported even by their own data. There are very few 
independent studies reporting on the short-term effects of HTP use. They 
indicate some short-term physiopathological effect (24–26).
Effects of HTP use on health
8Key messages
 HTPs contain tobacco and emit nicotine and other toxicants.
 HTPs generate a mainstream emission and a side-stream emission. Inhaling 
the mainstream emission exposes HTP users to the toxicants contained 
in the emission. Bystanders may inhale the side-stream or second-hand 
emissions. 
 Currently there is insufficient evidence to conclude that HTPs are less 
harmful than conventional cigarettes. In fact, there are concerns that while 
they may expose users to lower levels of some toxicants than conventional 
cigarettes, they also expose users to higher levels of other toxicants. It is 
not clear how this toxicological profile translates into short- and long-term 
health effects.
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Governments should introduce a system for the pre-market assessment of 
novel tobacco products, including HTPs. Marketing of HTPs should not be 
permitted unless there is conclusive evidence that compared to conventional 
cigarettes, the product reduces exposure to harmful and potentially harmful 
components and reduces health risks.
Governments that cannot prevent the introduction of HTPs in their markets 
or decide to allow the marketing of HTPs in the absence of such evidence 
should ensure the tobacco industry cannot claim government authorization 
of the product as its endorsement.  
In addition, HTPs should be taxed similarly to other tobacco products, following 
the recommendations of the Conference of the Parties to the WHO Framework 
Convention on Tobacco Control (WHO FCTC) in its decision FCTC/COP8(22) (29).  
The decision recognized HTPs as tobacco products and therefore considers 
them to be subject to the provisions of the WHO FCTC. The decision also 
reminded Parties to prioritize the following measures in accordance with the 
WHO FCTC and national law:
 prevent the initiation of HTP use;
 protect people from exposure to HTP emissions and explicitly extend the 
scope of smoke-free legislation to these products in accordance with 
Article 8 of the WHO FCTC;
 prevent health claims being made about HTPs;
 apply measures regarding advertising, promotion and sponsorship of HTPs 
in accordance with Article 13 of the WHO FCTC;
 regulate the contents and disclosure of contents of HTPs in accordance 
with articles 9 and 10 of the WHO FCTC;
 protect tobacco-control policies and activities from all commercial and 
other vested interests related to HTPs, including interests of the tobacco 
industry, in accordance with Article 5.3 of the WHO FCTC; and
 regulate, including restrict, or prohibit, as appropriate, the manufacture, 
importation, distribution, presentation, sale and use of HTPs as appropriate to 
national laws, taking into account a high level of protection for human health.
Finally, it is important to monitor comprehensively not only market developments, 
but also the use of HTPs through inclusion of relevant questions in all 
appropriate surveys.
Conclusions
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